Leadership

Karen A. Dawes, Chairperson of the Board, has served as a director of Repligen since September 2005. She is currently President of Knowledgeable Decisions, LLC, a management consulting firm. Ms. Dawes served from 1999 to 2003 as Senior Vice President and U.S. Business Group Head for Bayer Corporation’s U.S. Pharmaceuticals Group. Prior to joining Bayer, she was Senior Vice President, Global Strategic Marketing, at Wyeth LLC (“Wyeth”), a pharmaceutical company (formerly known as American Home Products), where she held responsibility for worldwide strategic marketing. Ms. Dawes also served as Vice President, Commercial Operations for Genetics Institute, Inc., which was acquired by Wyeth in January 1997, designing and implementing that company’s initial commercialization strategy to launch BeneFIX^® and Neumega^®. Ms. Dawes began her pharmaceuticals industry career at Pfizer, Inc. where, from 1984 to 1994, she held a number of marketing positions, serving most recently as Vice President, Marketing of the Pratt Division. At Pfizer, she directed launches of Glucotrol^®/Glucotrol XL^®, Zoloft^®, and Cardura^®. Ms. Dawes also serves on the board of directors of two publicly traded companies: PaxMedica Therapeutics and Medicenna Therapeutics Corp, one private company, Vaccitech Limited, and on one not-for-profit company, Medicines 360. Ms. Dawes received a B.A. and M.A. in English from Simmons College and an M.B.A. from Harvard University Graduate School of Business. Ms. Dawes’ qualifications to sit on the Company’s Board include her extensive strategic experience in both a managerial and consulting capacity with pharmaceutical companies as well as her considerable commercial background.

Nicolas M. Barthelemy has served as a director of Repligen since June 2014. Mr. Barthelemy brings over 25 years of industry experience to the director role. Mr. Barthelemy served as President and CEO of bioTheranostics, a molecular diagnostics company, from September 2014 until February 2017. Prior to bioTheranostics, he served as President, Global Commercial Operations at Life Technologies, which was acquired by Thermo Fisher Scientific in February 2014. Prior to Life Technologies, Mr. Barthelemy was with Biogen Inc. (“Biogen”) for eight years, most recently as Vice President, Manufacturing and General Manager for the company’s manufacturing organization at Research Triangle Park. He began his career with Merck & Co., Inc. as a Senior Project Engineer, Vaccine Technology. In addition to Repligen, Mr. Barthelemy also serves on the board of directors of three publicly traded companies; Fluidigm Corporation, Twist Bioscience and 908 Devices Inc., and one privately held company; Biocare Medical LLC. He also serves as an advisor to Warburg Pincus, a private equity firm. Mr. Barthelemy received an M.S. in Chemical Engineering from the University of California, Berkeley, and an engineering degree from Ecole Supérieure de Physique et Chimie Industrielles, Paris. Mr. Barthelemy’s qualifications to sit on the Company’s Board include his extensive experience in the bioprocessing field, including large scale biologics manufacturing and commercialization of consumables used in bioprocessing.

Carrie Eglinton Manner has served as a director of Repligen since June 2020. She brings to the director role over 24 years of leadership experience across multiple disciplines. Ms. Eglinton Manner currently serves as Senior Vice President, Advanced Diagnostics at Quest Diagnostics, which she joined in 2017. Prior to Quest, Ms. Eglinton Manner held various roles of increasing scope and responsibility over a period of 20 years at GE Healthcare. From 2009 through 2016, she served as President & CEO of four distinct GE Healthcare global businesses in the areas of diagnostic imaging, lab services and medical devices, ranging in size from approximately $150 million to $3 billion in revenue. In her role at Quest Diagnostics, Ms. Eglinton Manner is responsible for growing the company’s nearly $2 billion genetic and molecular diagnostics portfolio, through innovation in specialty genetic offerings and services, productivity programs, key strategic alliances, and acquisitions. In addition to joining the Repligen board, Ms. Eglinton Manner serves as board director for the not-for-profit Thrive Networks, focused on advancing women and transforming health in underserved communities. Ms. Eglinton Manner holds a B.S. in Mechanical Engineering from the University of Notre Dame. Ms. Eglinton Manner’s qualifications to sit on the Company’s Board include her track record of delivering business expansion and profitability for rapidly growing global businesses, including her experience with integrating acquisitions and building operations excellence, with a commitment to quality and process improvements.

Tony J. Hunt was named President and CEO and has served on the Board since May 2015. He joined Repligen in May 2014 as Chief Operating Officer, overseeing commercial and manufacturing operations. Before coming to Repligen, Mr. Hunt was President of Bioproduction at Life Technologies, a global life sciences company which was acquired by Thermo Fisher Scientific in 2014. He joined Life Technologies in 2008, serving as General Manager of Bioproduction Chromatography and Pharma Analytics before being named President of Bioproduction in 2011. From 2000 to 2008, Mr. Hunt was with Applied Biosystems as Senior Director of Pharma Programs where he launched the Pharma Analytics business that in 2008 became a part of the Bioproduction platform at Life Technologies. Mr. Hunt received a B.S. in Microbiology and an M.S. in Biotechnology from University College in Galway, Ireland, and an M.B.A. from Boston University School of Management. Mr. Hunt brings to the Board his deep understanding of the bioprocessing market.

Rohin Mhatre, Ph.D., was appointed to the Board in March 2020. Dr. Mhatre brings over 25 years of relevant experience to the director role, including his current position since January 2017, as Senior Vice President, Product and Technology Development at Biogen. He has held numerous other roles of increasing responsibility within Biogen, which he joined in 1996, including six years as Vice President of Biopharmaceutical Development, where he led a 300-member team responsible for cell line, cell culture, purification and device development. Earlier in Dr. Mhatre’s career at Biogen, he focused on building out analytical development and technical services. Prior to Biogen, Dr. Mhatre led the purification and applications group at Applied BioSystems (formerly Perspective Biosystems). Dr. Mhatre holds a Ph.D. in Chemistry from Northeastern University. Dr. Mhatre’s qualifications to sit on the Company’s Board of Directors include his extensive technical expertise, his leadership abilities and his deep understanding of the dependencies between biological drug development and efficient manufacturing workflows.

Glenn P. Muir has served as a director of Repligen since October 2015. Mr. Muir brings over 30 years of experience to the director role, including 26 years with Hologic, Inc., a large multi-national medical device and diagnostics company where he most recently served as Chief Financial Officer and Executive Vice President. Mr. Muir retired in May 2014 from Hologic, where he helped steer the company’s evolution from a venture-backed single product company to a publicly traded diversified organization with over 5,000 employees and $2.5 billion in revenue. He joined Hologic in 1988 and served as Chief Financial Officer since 1992 and Executive Vice President since 2000. Prior to Hologic, Mr. Muir was with Metallon Engineered Materials Co., a private company where from 1986-1988 he held the role of Vice President, Finance. Previously, from 1981-1984, he was a Senior Auditor with Arthur Andersen & Co. Mr. Muir also serves on the board of directors of two publicly traded companies; medical technology company Neuronetics, Inc. and life science company G1 Therapeutics, Inc. Previously, Mr. Muir served on the board of directors of ReWalk Robotics Ltd. from July 2014 to December 2017. Mr. Muir is a Certified Public Accountant with a Bachelors of Business Administration from the University of Massachusetts, Amherst. He also earned an M.S. from Bentley University and an M.B.A. from Harvard University. Mr. Muir’s qualifications to sit on Repligen’s Board of Directors include his extensive experience with integrating strategic acquisitions and leading the financial operations for a global manufacturing and commercial organization.

Thomas F. Ryan Jr. has served as a director of Repligen since September 2003. Mr. Ryan is currently an investor in various private companies. Mr. Ryan served as the President and Chief Operating Officer of the American Stock Exchange from October 1995 to April 1999. Prior to 1995, he held a variety of positions at the investment banking firm of Kidder, Peabody & Co., Inc., serving as the firm’s Chairman in 1995. He holds a B.A. from Boston College and is a graduate of the Boston Latin School. Mr. Ryan is a director for the New York State Independent System Operator and a director for BNY Mellon Asset Management Mutual Funds Board. Mr. Ryan’s qualifications to sit on the Company’s Board of Directors include his years of experience in the areas of securities trading and investment banking.

Richard D. Braatz is the Edwin R. Gilliland Professor at the Massachusetts Institute of Technology (MIT) where he does research in process data analytics, design, and control of advanced manufacturing systems. He received MS and Ph.D. from the California Institute of Technology and was the Millennium Chair and Professor at the University of Illinois at Urbana-Champaign and a Visiting Scholar at Harvard University before moving to MIT. He has consulted and/or collaborated with more than 30 companies including Merck, Novartis, Pfizer, Amgen, Biogen, and Bristol-Myers Squibb. He is a member of the National Academy of Engineering.

Charles L. Cooney is the Robert T. Haslam (1911) Professor of Chemical and Biochemical Engineering, Emeritus in the Department of Chemical Engineering at MIT and founding Faculty Director, Emeritus of the Deshpande Center for Technological Innovation at MIT. With a BS in chemical engineering from the University of Pennsylvania and an SM and Ph.D. in Biochemical engineering from MIT, he has spent his professional career on the MIT faculty. He is an expert in process design, upstream and downstream bioprocess development, and manufacturing of pharmaceutical and biological products.  Prof. Cooney has served as a consultant to or board member of multiple biotech and pharmaceutical companies and is chairman of Repligen’s Scientific Advisory Board.

Dr. Cramer is the William Weightman Walker Professor at Rensselaer Polytechnic Institute and is known for his contributions to the separation of complex biological products and the development of chromatographic materials, processes and predictive tools for enabling their biomanufacturing. In addition, he has made seminal contributions to the molecular understanding of the interactions that create unique selectivities in these separation systems. His lab is currently conducting research on several areas related to protein-surface interactions including prediction of protein binding affinity and multiscale modeling of chromatographic systems, development of efficient antibody and bispecific antibody separation systems, fundamental studies in multimodal chromatography, multilevel automated peptide synthesis/screening system for design of affinity peptides, smart biopolymer affinity precipitation systems, biophysics of protein interactions with surfaces, ligands and proteins, platformable strategies for effective removal of process HCPs and integrated semi-continuous biomanufacturing processes. He was the editor of Separation Science and Technology for 20 years and has been awarded the Alan S. Michaels Award for the Recovery of Biological Products (ACS Division of Biochemical Technology) and the ACS National Award in Separation Science and Technology. He was also awarded Rensselaer’s Distinguished Faculty Award as well as the School of Engineering Outstanding Professor and Research Excellence Awards. Dr. Cramer has been elected a fellow of the American Association for the Advancement of Science, American Institute of Chemical Engineers, the American Chemical Society and the American Institute for Medical and Biological Engineering. 

Alfred Goldberg is a Professor of Cell Biology at Harvard Medical School. His research has concerned the mechanisms and regulation of protein breakdown in cells. His laboratory first demonstrated the existence of the non-lysosomal pathway for protein breakdown (now termed the ubiquitin-proteasome pathway), the 26S proteasome, and the ATP-dependent proteases responsible for protein degradation in bacteria. He also initiated the development of the proteasome inhibitor, Bortezomib/Velcade, now used worldwide for the treatment of multiple myeloma. His research accomplishments have been recognized with many honors, including three honorary degrees, the Gordon Alpert Prize, the Ernst Beutler Prize, and the 2021 Passano Award for Medical Research. He has been elected to the National Academy of Sciences, National Academy of Medicine, and American Academy of Arts & Sciences, and he is among the 0.01% most cited authors in the life sciences. Dr. Goldberg has served frequently as a consultant to biotech companies and for 7 years served on the Board of Directors of Repligen. 

Before joining Codiak, Konstantin Konstantinov was responsible for the late-stage bioprocess and technology development at Sanofi’s Boston Hub, including all functions, from cell banking to fill/finish/lyophilization. Prior to Sanofi, Dr. Konstantinov worked for Bayer in Berkeley, California for 14 years, advancing to the position of Head of Process Sciences. He has published 60 peer reviewed papers and has more than 15 patents and patent applications. During the last 23 years, Dr. Konstantinov has worked on the development and commercialization of various products, including monoclonal antibodies, blood factors and enzymes expressed in mammalian cells. Most recently, he has pioneered the development of an end-to-end integrated continuous biomanufacturing platform, which is becoming a strategic technological trend for the biomanufacturing industry worldwide. Dr. Konstantinov received his Ph.D. in Biochemical Engineering from Osaka University, Japan, which was followed by a post-doctoral assignment at DuPont and the University of Delaware.

J. Christopher Love is the Raymond A. (1921) and Helen E. St. Laurent Professor of Chemical Engineering and member of the Koch Institute for Integrative Cancer Research at MIT. In addition, he is an associate member at the Eli and Edythe L. Broad Institute, and at the Ragon Institute of MGH, MIT, and Harvard. Prof. Love received his Ph.D. in 2004 in physical chemistry at Harvard University. He extended his research into immunology at Harvard Medical School from 2004-2005, and at the Immune Disease Institute from 2005-2007. His research centers on using simple microsystems to monitor cells from clinical samples in chronic human diseases, and on developing new approaches to manufacturing biologic drugs and vaccines efficiently and affordably.  Prof. Love was named a Dana Scholar for Human Immunology and a Keck Distinguished Young Scholar in Medical Research in 2009, one of Popular Science’s Brilliant 10 in 2010, and also a Camille Dreyfus Teacher-Scholar. At MIT, he is the Director of the Alternative Host Consortium, a unique MIT-Industry partnership advancing new manufacturing hosts for biopharmaceuticals and vaccines. He previously served as a Distinguished Engineer in Residence at Biogen (2015-2016), and also consults for several biotechnology and biopharmaceutical companies, including three current start-ups based on technologies from his lab at MIT (Honeycomb, OneCyte, and Sunflower).